Ammonium Trichloro(dioxoethylene-o,o′)tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1843-1852

  Sredni, Benjamin ^a   Weil, Merav ^a   Khomenok, Gennadi ^a   Lebenthal, Ilana ^a   Teitz, Seagal ^b   Mardor, Yael ^c   Ram, Zvi ^d   Orenstein, Arie ^c   Kershenovich, Amir ^e   Michowiz, Shalom ^e   Cohen, Yan I ^e   Rappaport, Zvi H ^e   Freidkin, Ilya ^a   Albeck, Michael ^a   Longo, Dan L ^f   Kalechman, Yona ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

^f NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTISENSE OLIGONUCLEOTIDE; INTERLEUKIN 10; PACLITAXEL; PROTEIN BCL 2; STAT3 PROTEIN; AMMONIUM TRICHLORO(DIOXOETHYLENE O,O' )TELLURATE; AMMONIUM TRICHLORO(DIOXOETHYLENE-O,O'-)TELLURATE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ETHYLENE DERIVATIVE; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIZATION; GENETIC TRANSFECTION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SCID MOUSE; SOLID TUMOR; STOMACH ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; EXPERIMENTAL MELANOMA; METABOLISM; MOUSE MUTANT; NEOPLASM; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; ETHYLENES; HUMANS; INTERLEUKIN-10; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 12144289718     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3179     Document Type: Article

References (47)

1. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., and Blay, J. Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today, 18: 493-497, 1997.
2. Pawelec, G., Zeuthen, J., and Kiessling, R. Escape from host antitumor immunity. Crit. Rev. Oncol., 8: 111-141, 1997.
3. Yue, F. Y., Dummer, R., Geertsen, R., Hofbauer, G., Laine, E., Manolio, S., and Burg, G. IL-10 is a growth factor for human melanoma cells and down-regulates HLA class I, HLA class II, and ICAM-1 molecules. Int. J. Cancer, 71: 630-637, 1997.
4. Nakagomi, H., Pisa, P., Pisa, E. K., Yamamoto, Y., Halapi, E., Backlin, K., Juhlin, C., and Kiessling, R. Lack of IL-2 expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer. 63: 366-371, 1995.
5. Galizia, G., Orditura, M., Romano, C., Lieto, E., Castellano, P., Pelosio, L., Imperatore, V., Catalano, G., Pignatelli, C., and De Vita, F. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol., 102: 169-178, 2002.
6. Huettner, C., Czub, S., Kerkau, S., Roggendorf, W., and Tonn, J. C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res., 17: 3217-3224, 1997.
7. De Vita, F., Orditura, M., Galizia, G., Romano, C., Roscigno, A., Lieto, E., and Catalano, G. Serum IL-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117: 365-373, 2000.
8. De Waal Malefyt, R., Yssel, H., Roncarolo, M., Spits, H., and de Vries, J. E. Interleukin-10. Curr. Opin. Immunol., 4: 314-320, 1992.
9. Maeda, H., and Shiraishi, A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol., 156: 73-78, 1996.
10. Blay, J. Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J., and Favrot, M. Serum IL-10 in non-Hodgkin's lymphoma a prognostic factor. Blood, 82: 2169-2174, 1993.
11. Fortis, C., Foppoli, M., Gianotti, L., Galli, L., Citterio, G., Consogno, G., Gentilini, O., and Braga, M. Increased IL-10 serum levels in patients with solid tumors. Cancer Lett., 104: 1-5, 1996.
12. Garcia-Hernandez, M. L., Hernandez-Pando, R., Gariglio, P., and Berumen, J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumor and vascular cell proliferation. Immunology, 105: 231-243, 2002.
13. Finbloom, D. S., and Winestock, K. D. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STATIα and STAT3 complexes in human T cells and monocytes. J. Immunol., 155: 1079-1079, 1995.
14. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Investig., 109: 1139-1142, 2002.
15. Strassmann, G., Kambayashi, T., Jacob, C. O., and Sredni, D. The immunomodulator AS101 inhibits IL-10 release and augments TNF α release by mouse and human mononuclear phagocytes. Cell. Immunol., 176: 180-185, 1997.
16. Sredni, B., Caspi, R. R., Klein, A., Kalechman, Y., Danziger, Y., Ben Ya'akov, M., Tamari, T., Shalit, F., and Albeck, M. A new immunomodulating compound (AS101) with potential therapeutic application. Nature (Lond.), 330: 173-176, 1987.
17. Kalechman, Y., Zuloff, A., Albeck, M., Strassmann, G., and Sredni, B. Role of endogenous cytokine secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-o,o′)tellurate. Blood, 85: 1555-156, 1995.
18. Kalechman, Y., Sredni, B., Weinstein, T., Freidkin, I., Tobar, A., Albeck, M., and Gafter, U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101: role in experimental mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol., 14: 620-630, 2003.
19. Rosenblatt-Bin, H., Kalechman, Y., Vonsover, A., Xu, R. H., Da, J. P., Shalit, F., Huberman, M., Klein. A., Strassmann, G., Albeck, M., and Sredni, B. The immunomodulator AS101 restores TH1 type of response suppressed by Babesia rodhaini in Balb/c mice. Cell. Immunol., 184: 12-25, 1998.
20. Kalechman, Y., Gafter, U., Da, J. P., Albeck, M., Alarcon-Segovia, D., and Sredni, B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNFα levels. J. Immunol., 159: 2658-2667, 1997.
21. Kalechman, Y., Gafter, U., Gal, R., Rushkin, G., Yan, D., Albeck, M., and Sredni, B. Anti IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J. Immunol., 169: 384-392, 2002.
22. Sredni, B., Shani, A., Catane, R., Kaufman, B., Strassmann, G., Albeck, M., and Kalechman, Y. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J. Natl. Cancer Inst., 88: 1276-1284, 1996.
23. Kalechman, Y., Longo, D. L., Catane, R., Shani, A., Albeck, M., and Sredni, B. Synergistic anti-tumoral effect of Taxol + AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int. J. Cancer, 86: 281-288, 2000.
24. Kalechman, Y., Sotnik-Barkai, I., Albeck, M., and Sredni, B. The protective role of AS101 in combination with several cytotoxic drugs acting by different mechanisms of action. Cancer Res., 53: 5962-5969, 1993.
25. Sredni, B., Albeck, M., Tichler, T., Shani, A., Shapira, J., Bruderman, I., Catane, R., Kaufman, B., and Kalechman. Y. Bone marrow sparing and prevention of alopecia by AS101 in NSCL cancer patients treated with carboplatin and etoposide. J. Clin. Oncol., 13: 2342-2353, 1995.
26. Ruvolo, P. P., Deng, X., and May, W. S. Phosphorylation of Bcl-2 and regulation of apoptosis. Leukemia, 15: 515-522, 2001.
27. Stephanou, A., Brar, B. K., Knight, R. A., and Latchman. D. S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ., 7: 329-330, 2000.
28. Chamberlain, M. C., and Kormanik, P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J. Clin. Oncol., 13: 2066-2071, 1995.
29. Gu, Z. J., Costes, V., Lu, Z. Y., Zhang, X. G., Pitard, V., Moreau, J. F., Bataille, R., Wijdenes, J., Rossi, J. F., and Klein, B. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood, 88: 3972-3986, 1996.
30. Galizia, G., Lieto, E., De Vita, F., Romano, C., Orditura, M., Castellano, P., Imperatore. V., Infusino, S., Catalano, G., and Pignatelli, C. Circulating levels of IL-10 and IL-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J. Interferon cytokine Res., 22: 473-482, 2002.
31. Sarris, A. H., Klische, K. O., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., Messina, O., Pugh, W., Hagemeister, F. B., McLaughlin, P., Rodriguez, M. A., Romaguera, J., Fritsche, H., Witzig, T., Duvic, M., Andreeff, M., and Cabanillas, F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol., 10: 433-440, 1999.
32. O'Farrell, A., Liu, Y., Moore, K. W., and Mui, L. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and independent pathways. EMBO J., 17: 1006-1018, 1998.
33. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther., 82: 231-239, 1999.
34. Buettner, R., Mora, L. B., and Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res., 8: 945-954, 2002.
35. Ivanov, V. N., Bhoumik, M. K., Raz, R., Owen-Schaub, L. B., Levy, D., Horvath, C. M., and Ronai, Z. Cooperation between STAT3 and c-Jun suppresses Fas transcription. Mol. Cell., 7: 517-528, 2001.
36. Kalechman, Y., Strassmann, G., Albeck, M., and Sredni, B. Up-regulation by ammonium trichloro(dioxoethylene-o,o[primes])tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J. Immunol., 161: 3536-3542, 1998.
37. Cohen, S. B. A., Crawley, J. B., Kahan, M. C., Feldmann, M., and Foxwell, B. M. Interleukin-10 rescues T cells from apoptotic cell death: association with upregulation of Bcl-2. Immunology, 92: 1-5, 1997.
38. Alas, S., and Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (stat3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res., 61: 5137-5144, 2001.
39. Ogura, E., Senzaki, H., Yamamoto, D., Yoshida, R., Takada, H., Hioki, K., and Tsubura, A. Prognostic significance of Bcl-2, Bcl-xLS, Bax and Bak expressions in colorectal carcinomas. Oncol. Rep., 6: 365-369, 1999.
40. Stassi, G., Todaro, M., Zerilli, M., Ricci-Vitiani, L., Di Liberto, D., Patti. M., Florena, A., Di Gaudio, F., Di Gesu, G., and De Maria, R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res., 63: 6784-6790, 2003.
41. Niu, G., Shain, K. H., Huang, M., Ravi, R., Bedi, A., Dalton, W. S., Jove, R., and Yu, H. Overexpression of a dominant negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res., 61: 3276-3280, 2001.
42. Silbergeld, D. L., Chicoine, M. R., and Madsen, C. L. In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion. Anticancer Drug, 6: 270-276, 1995.
43. Lederman, G., Wronski, M., Arbit, E., Odaimi, M., Wertheim, S., Lombardi, E., and Wrzolek, M. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am. J. Clin. Oncol., 23: 155-159, 2000.
44. Hara, A., Hirose, Y., Yoshimi, N., Tanaka, T., and Mori. H. Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol. Res., 19: 623-628, 1997.
45. Julien, T., Frankel, B., Longo, S., Kyle, M., Gibson, S., Shillitoe, E., and Ryken, T. Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg. Neurol., 53: 360-369, 2000.
46. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
47. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q. J., Masucci, M. G., and Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180: 2371-2376, 1994.